Document is current
Any future updates will be listed below
-
Authors
Hristovska, Ines
Pichet Binette, Alexa
Kumar, Atul https://orcid.org/0000-0002-2166-4805
Wennström, Malin
Gaiteri, Chris
Karlsson, Linda https://orcid.org/0000-0002-0630-772X
Strandberg, Olof
Janelidze, Shorena https://orcid.org/0000-0003-2869-8378
van Westen, Danielle https://orcid.org/0000-0001-8649-9874
Stomrud, Erik
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Ossenkoppele, Rik https://orcid.org/0000-0003-1584-7477
Mattsson-Carlgren, Niklas https://orcid.org/0000-0002-8885-7724
Vogel, Jacob W. https://orcid.org/0000-0001-6394-9940
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 29 January 2026
First Online: 24 February 2026
Competing interests
: O.H. is an employee of Eli Lilly and Lund University, and he has previously acquired research support (for Lund University) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2 years, he has received consultancy/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. S.P. has acquired research support (for the institution) from ki elements/ADDF. In the past 2 years, he has received consultancy/speaker fees from BioArtic, Biogen, Lilly and Roche. J.W.V. has received consultancy/speaker fees from Manifest Technologies and Prothena Corp. The remaining others declare no competing interests.
